A Food and Drug Administration (FDA) expert panel has reignited a debate over whether hormone therapy should be used to treat ...

The FDA may remove the warning labels on hormone replacement therapies used to treat the symptoms of menopause. Doctors say ...

CBER is unanimously against Elevdiys’ return to the market without additional evidence, according to media reports citing an ...

For Sarepta, the hits keep coming, with several downgrades in the past week after it was forced to temporarily take its ...

Switzerland’s new regulation represents a massive experiment in pushing back against this inclination, forcing people to ...

Wall Street analysts warn that if Sarepta Therapeutics doesn't resolve the Elevidys issues, it could jeopardize its ability to repay debt in 2027.